Detailed definition
Perimenopause is associated with a 2–4× increased risk of depressive symptoms compared to premenopausal years, with the highest risk in late perimenopause and early postmenopause. Mechanisms include: direct estrogen modulation of serotonin and norepinephrine neurotransmission and BDNF expression; sleep fragmentation from night sweats; HPA-axis dysregulation; cognitive symptoms reducing self-efficacy; and life-stage factors (caregiving, career transitions, relationship changes). Anxiety and irritability are often more prominent in perimenopause than classic depression. Treatment options include: HRT, particularly for women whose mood symptoms began with the menopause transition and overlap with vasomotor symptoms; SSRIs/SNRIs (which also reduce vasomotor symptoms at appropriate doses); CBT; exercise (high-quality evidence for mood); and addressing sleep and any underlying thyroid issues. NAMS does not recommend HRT as monotherapy for major depression but supports it as an adjunct or option for perimenopausal mood symptoms in the right context.
Why it matters in menopause
Many women in perimenopause are started on SSRIs by primary care without ever being offered HRT. For women whose mood symptoms began alongside hot flashes and sleep disruption, treating the underlying menopause physiology often resolves the mood symptoms — or at least allows lower-dose SSRI therapy. ClearedRx integrates mood screening into intake and prescribes accordingly.
Related terms
Sources
External references: Wikipedia.